Kết quả bước đầu phác đồ hóa trị dẫn đầu gemcitabincisplatin và hóa xạ trị đồng thời ung thư vòm mũi họng giai đoạn III-IVA

To evaluate the preliminary results of induction chemotherapy regimen gemcitabincisplatin followed by concurrent chemoradiotherapy in stage III-IVA nasopharyngeal carcinoma patients. Subject and method: The uncontrolled clinical intervention was conducted on 41 stage III-IVA nasopharyngeal carcinoma patients (with N3 accounting for 46.3%) who underwent induction chemotherapy with 3 cycles of gemcitabin 1000mg/m2 on day 1 and 8 plus cisplatin 80mg/m2 on day 1, followed by concurrent radiotherapy with weekly cisplatin 40mg/m2 from March 2020 to February 2023 at the 108 Military Central Hospital. Result: At 1 month after radiotherapy, the complete and partial response rates were 92.7% and 7.3%, respectively. The median follow-up time was 16 months (range: 6- 33 months). The rates of locoregional relapse-free survival, disease-free survival, distant metastasis-free survival, and overall survival at 2 years were 85.2%, 66.9%, 82.9%, and 92.3%, respectively. Grade 3-4 hematologic toxicity occurred commonly (51.3%), mainly manifested as neutropenia. Conclusion: The induction chemotherapy with gemcitabine-cisplatin followed by concurrent radiotherapy for the treatment of advanced-stage nasopharyngeal carcinoma initially achieved relatively high rates of locoregional control and distant metastasis-free survival. However, this regimen was associated with a high incidence of hematologic toxicity.